Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05952557 · ClinicalTrials.gov registry record · Phase 3

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

A Phase 3 study of Breast Cancer, Early Breast Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
5,500
Enrollment target
20
Study locations

NCT05952557: Recruiting Phase 3 study of Breast Cancer, Early Breast Cancer, sponsored by AstraZeneca.

NCT05952557 is a Phase 3 study of Breast Cancer, Early Breast Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 5,500 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (612% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05952557, a Phase 3 study of Breast Cancer, Early Breast Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
5,500 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.

Primary Outcome

IBCFS is defined as time from randomisation until date of first occurrence of: * Invasive ipsilateral breast tumour recurrence * Locoregional invasive breast cancer recurrence * Distant recurrence * Contralateral invasive breast cancer * Death attributable to any cause.

Conditions Studied

Breast Cancer, Early Breast Cancer

Interventions

  • DRUG Camizestrant
  • DRUG Tamoxifen
  • DRUG Anastrozole
  • DRUG Letrozole
  • DRUG Exemestane

Study Locations (20)

California

  • Research Site - Duarte
  • Research Site - Fountain Valley
  • Research Site - Greenbrae
  • Research Site - Irvine
  • Research Site - La Jolla
  • Research Site - Los Angeles
  • Research Site - Monterey
  • Research Site - Walnut Creek
  • Research Site - West Hollywood

Colorado

  • Research Site - Aurora
  • Research Site - Littleton
  • Research Site - Littleton

Arizona

  • Research Site - Phoenix
  • Research Site - Tucson

Alabama

  • Research Site - Dothan

Arkansas

  • Research Site - Fayetteville

Connecticut

  • Research Site - New Haven

Delaware

  • Research Site - Newark

District of Columbia

  • Research Site - Washington D.C.

Trial Details

FieldValue
Enrollment Target 5,500 participants
Start Date 2023-10-05
Est. Completion 2037-05-06
Phase Phase 3
AstraZeneca

1,285 total trials

What NCT05952557 shows while recruiting

NCT05952557 is an interventional study that assigns participants to a tested intervention. Its 5,500 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (612% higher).

The record links to 1 condition, with Breast Cancer, Early Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Camizestrant is the first listed.

NCT05952557 names 20 study sites across 9 states, led by California, Colorado, Arizona.

Frequently Asked Questions

What is clinical trial NCT05952557 about?

NCT05952557 is a clinical study titled "An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)". This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without c...

What is the current status of trial NCT05952557?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,500 participants. The study started on 2023-10-05. Estimated completion is 2037-05-06.

What conditions does trial NCT05952557 study?

This clinical trial studies the following conditions: Breast Cancer, Early Breast Cancer.

What interventions are being tested in trial NCT05952557?

The interventions under investigation include: Camizestrant (DRUG), Tamoxifen (DRUG), Anastrozole (DRUG), Letrozole (DRUG), Exemestane (DRUG).

Who is sponsoring clinical trial NCT05952557?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05952557 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer, Early Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05952557's enrollment target sits among peer trials

5,500 44th of 2000 higher than 1,957 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06084234 · 5,500 participants · Phase 4

    National Liver Cancer Screening Trial

  • NCT07146568 · 5,515 participants · NA

    Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital

  • NCT04295486 · 5,478 participants · Phase 2

    Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

  • NCT06981598 · 5,586 participants · NA

    Prevention of Psychological Health Problems Via Integrated Operational Support

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05952557

Source: ClinicalTrials.gov NCT05952557, the US trial registry maintained by the National Library of Medicine. NCT05952557 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.